v3.26.1
STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Income Statement [Abstract]    
Collaboration revenue $ 7,945,753 $ 3,554,061
Operating expenses:    
Research and development [1] 16,734,549 11,865,654
In-process research and development 2,289,602 25,000
General and administrative 11,449,466 8,885,757
Depreciation 27,361 27,361
Total operating expenses 30,500,978 20,803,772
Loss from operations (22,555,225) (17,249,711)
Other income:    
Other income 1,332,207 1,648,637
Pre-tax loss (21,223,018) (15,601,074)
Income tax (expense) benefit (3,089) 720,287
Net loss $ (21,226,107) $ (14,880,787)
Share information:    
Net loss per share of common stock, basic $ (1.27) $ (0.98)
Net loss per share of common stock, diluted $ (1.27) $ (0.98)
Weighted-average shares of common stock outstanding, basic 16,730,274 15,238,919
Weighted-average shares of common stock outstanding, diluted 16,730,274 15,238,919
[1] External research and development expenses include: fees paid to CROs, CMOs and research laboratories, process development, manufacturing and clinical development activities. Any internal research and development expenses associated with clinical product candidates are captioned as internal research and development expenses.